Trulieve Cannabis Corp. (CSE:TRUL) shares have continued their recent momentum with a 97% gain in the last month alone. Notwithstanding the latest gain, the annual share price return of 7.5% isn’t as impressive.
Even after such a large jump in price, there still wouldn’t be many who think Trulieve Cannabis’ price-to-sales (or “P/S”) ratio of 1.5x is worth a mention when the median P/S in Canada’s Pharmaceuticals industry is similar at about 1.1x. However, investors might be overlooking a clear opportunity or potential setback if there is no rational basis for the P/S.
See our latest analysis for Trulieve Cannabis
What Does Trulieve Cannabis’ P/S Mean For Shareholders?
With revenue growth that’s inferior to most other companies of late, Trulieve…
